Description

Triductan MV (trimetazidine) Coated Tablets with Prolonged Release 35 mg. №20

Ingredients

Active ingredient: Trimetazidine 35 mg.
Other ingredients: lactose monohydrate, hypromellose, colloidal anhydrous silica, magnesium stearate, macrogol, talc, titanium dioxide (E171), iron oxide yellow (E172), methacrylic acid-ethyl acrylate copolymer, triethyl citrate.

Dosage

Recommended dosage: 1 tablet daily, swallowed whole with water, preferably during meals.

Indications

Triductan MV is indicated for the symptomatic treatment of patients with stable angina pectoris.

Contraindications

Do not use Triductan MV if you are hypersensitive to trimetazidine or any of the other ingredients. Consult a healthcare professional before use.

Directions

For oral use. Swallow the tablet whole with water, without chewing. It is recommended to take the tablet during meals.

Scientific Evidence

Trimetazidine, the active ingredient in Triductan MV, has been extensively studied for its efficacy in the treatment of stable angina. Research has shown that trimetazidine improves myocardial glucose utilization, reduces the frequency of angina attacks, and improves exercise tolerance in patients with stable angina.

Additional Information

It is important to note that Triductan MV is a prolonged-release formulation, providing a sustained release of trimetazidine over time, ensuring a consistent therapeutic effect. Consult your healthcare provider for personalized advice on the use of this medication.

Pharmacological Effects: Trimetazidine acts by shifting myocardial metabolism from fatty acid oxidation to glucose oxidation, thereby preserving energy metabolism in the ischemic myocardium. This results in improved cardiac function and reduced ischemic damage.

Clinical Trials: Clinical trials have demonstrated the efficacy of trimetazidine in reducing the frequency of angina attacks and improving exercise capacity in patients with stable angina. A study by Danchin et al. (2006) showed that trimetazidine significantly reduced the number of weekly angina attacks and nitroglycerin consumption compared to placebo.